TY - JOUR
T1 - Randomized, multicenter, phase ii study of co-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma
T2 - Including a prospective evaluation of the role of hENT1 in gemcitabine or CO-101 sensitivity
AU - Poplin, Elizabeth
AU - Wasan, Harpreet
AU - Rolfe, Lindsey
AU - Raponi, Mitch
AU - Ikdahl, Tone
AU - Bondarenko, Ihor
AU - Davidenko, Irina
AU - Bondar, Volodymyr
AU - Garin, August
AU - Boeck, Stefan
AU - Ormanns, Steffen
AU - Heinemann, Volker
AU - Bassi, Claudio
AU - Evans, T. R.Jeffrey
AU - Andersson, Roland
AU - Hahn, Hejin
AU - Picozzi, Vince
AU - Dicker, Adam
AU - Mann, Elaina
AU - Voong, Cynthia
AU - Kaur, Paramjit
AU - Isaacson, Jeff
AU - Allen, Andrew
PY - 2013/12/10
Y1 - 2013/12/10
N2 - Purpose Gemcitabine requires transporter proteins to cross cell membranes. Low expression of human equilibrative nucleoside transporter-1 (hENT1) may result in gemcitabine resistance in pancreatic ductal adenocarcinoma (PDAC). CO-101, a lipid-drug conjugate of gemcitabine, was rationally designed to enter cells independently of hENT1. We conducted a randomized controlled trial to determine whether CO-101 improved survival versus gemcitabine in patients with metastatic PDAC (mPDAC) with low hENT1. The study also tested the hypothesis that gemcitabine is more active in patients with mPDAC tumors with high versus low hENT1 expression. Patients and Methods Patients were randomly assigned to CO-101 or gemcitabine, after providing a metastasis sample for blinded hENT1 assessment. An immunohistochemistry test measuring tumor hENT1 was developed. To dichotomize the population, an hENT1 cutoff value was defined using primary PDAC samples from an adjuvant trial, and a high/low cutoff was applied. The primary end point was overall survival (OS) in the low hENT1 subgroup. Results Of 367 patients enrolled, hENT1 status was measured in 358 patients (97.5%). Two hundred thirty-two (64.8%) of 358 patients were hENT1 low. There was no difference in OS between treatments in the low hENT1 subgroup or overall, with hazard ratios (HRs) of 0.994 (95% CI, 0.746 to 1.326) and 1.072 (95% CI, 0.856 to 1.344), respectively. The toxicity profiles in both arms were similar. Within the gemcitabine arm, there was no difference in survival between the high and low hENT1 subgroups (HR, 1.147; 95% CI, 0.809 to 1.626). Conclusion CO-101 is not superior to gemcitabine in patients with mPDAC and low tumor hENT1. Metastasis hENT1 expression did not predict gemcitabine outcome.
AB - Purpose Gemcitabine requires transporter proteins to cross cell membranes. Low expression of human equilibrative nucleoside transporter-1 (hENT1) may result in gemcitabine resistance in pancreatic ductal adenocarcinoma (PDAC). CO-101, a lipid-drug conjugate of gemcitabine, was rationally designed to enter cells independently of hENT1. We conducted a randomized controlled trial to determine whether CO-101 improved survival versus gemcitabine in patients with metastatic PDAC (mPDAC) with low hENT1. The study also tested the hypothesis that gemcitabine is more active in patients with mPDAC tumors with high versus low hENT1 expression. Patients and Methods Patients were randomly assigned to CO-101 or gemcitabine, after providing a metastasis sample for blinded hENT1 assessment. An immunohistochemistry test measuring tumor hENT1 was developed. To dichotomize the population, an hENT1 cutoff value was defined using primary PDAC samples from an adjuvant trial, and a high/low cutoff was applied. The primary end point was overall survival (OS) in the low hENT1 subgroup. Results Of 367 patients enrolled, hENT1 status was measured in 358 patients (97.5%). Two hundred thirty-two (64.8%) of 358 patients were hENT1 low. There was no difference in OS between treatments in the low hENT1 subgroup or overall, with hazard ratios (HRs) of 0.994 (95% CI, 0.746 to 1.326) and 1.072 (95% CI, 0.856 to 1.344), respectively. The toxicity profiles in both arms were similar. Within the gemcitabine arm, there was no difference in survival between the high and low hENT1 subgroups (HR, 1.147; 95% CI, 0.809 to 1.626). Conclusion CO-101 is not superior to gemcitabine in patients with mPDAC and low tumor hENT1. Metastasis hENT1 expression did not predict gemcitabine outcome.
UR - http://www.scopus.com/inward/record.url?scp=84894297251&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84894297251&partnerID=8YFLogxK
U2 - 10.1200/JCO.2013.51.0826
DO - 10.1200/JCO.2013.51.0826
M3 - Article
C2 - 24220555
AN - SCOPUS:84894297251
SN - 0732-183X
VL - 31
SP - 4453
EP - 4461
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 35
ER -